Publication hold · product and protocol verification
Rejuran in Seoul
This page is retained to explain product identity, evidence limits, and questions to verify before planning. It does not confirm clinic availability, variants, a protocol, a price, or an outcome timeline.
Board-Certified
Dermatologist
AAD International Fellow
IFAAD
- Duration
- Set after assessment
- Sessions
- No universal course
- Downtime
- Varies by plan
Rejuran Overview
PN and PDRN are not interchangeable evidence categories. Findings about adenosine A2A signaling or nucleotide salvage reported for PDRN cannot automatically be transferred to PN or a Rejuran product. Product-specific clinic details remain unpublished pending operator and physician confirmation.
Best for
- Product identity and evidence limits
- Questions to verify before treatment planning
Suited for
- People seeking a product- and route-specific review before deciding whether to proceed
- Duration
Set after assessment
- Sessions
No universal course
- Downtime
Varies by plan
- Peak result
Reassessed over time
How Rejuran Works
01
First verify the exact product, indication, route, and supporting records.
02
Only then discuss an individualized plan, alternatives, risks, recovery, and cost.
01
First verify the exact product, indication, route, and supporting records.
02
Only then discuss an individualized plan, alternatives, risks, recovery, and cost.
“Injectables and energy devices are performed by physicians — never delegated to non-physician staff. The clinic is led by a board-certified dermatologist.”
Rejuran Before & After
Cases shown are Fitzpatrick III–IV (East Asian skin). Results in lighter (I–II) or darker (V–VI) skin types may differ — discussed at consultation.
FAQ
Are PN and PDRN the same evidence category?
No. Findings about adenosine A2A signaling or nucleotide salvage reported for PDRN cannot automatically be transferred to PN or a Rejuran product. Product identity and product-specific human evidence must be assessed separately.
Does this page confirm a variant, schedule, price, or availability?
No. Exact variants, clinic availability, prices, dose, route, intervals, course, peak timing, durability, and maintenance remain unpublished until the operator and physician approve the supporting records.
What can be concluded about safety?
An absence of an event in a small study cannot exclude uncommon or serious complications. A safety discussion must match the exact product, route, anatomy, protocol, alternatives, and consent information.
Session summary & comparison
| Item | Details |
|---|---|
| Duration | Set after assessment |
| Sessions | No universal course |
| Downtime | Varies by plan |
| Peak result | Reassessed over time |
For your visit
- Do not plan travel around a fixed recovery or result timeline until the exact product and proposed plan are confirmed.
Related procedures
Evidence & comparison guides
Need another answer before deciding?
You do not need to read every guide. Open the question that still matters to your decision.
Optional decision guides
- Comparison guideSculptra vs Skin Boosters Seoul | Evidence-Based GuideCompare Sculptra with Rejuran PN, Skinvive and Profhilo by treatment goal, published evidence, U.S. FDA status and practical questions to ask in Seoul.
- Comparison guideDermatology Downtime Guide Seoul | Recovery TimelinesRecovery timelines for Ultherapy, Thermage, fillers, lasers, and more in Seoul. Published clinical data, combination spacing, and flight-timing advice.
Clinic articles
- Clinic articleIs Rejuran PN or PDRN? Evidence, FDA Status & Seoul GuideRejuran is a polynucleotide (PN) injectable, not simply another name for PDRN. See the 2026 evidence, U.S. FDA status, risks, and what to ask in Seoul.
- Clinic articleSculptra Master, Thermage TTT & Rejuran VIP CertificationsOur board-certified dermatologist holds top-tier Sculptra, Thermage FLX, and Rejuran certifications — awarded only to clinics with proven clinical experience.
- Clinic articleWhy Hand Technique Decides Your Injectable Outcome (2026 Review)Why hand technique decides your injectable outcome — a 2026 dermatologist's evidence review of cannula-vs-needle, dose-response, and intradermal placement.
- Clinic articleJUVELOOK vs Rejuran: Evidence—and Where Exosomes FitCompare JUVELOOK PDLLA-HA, Rejuran PN and topical exosome adjuncts by ingredient, evidence, risks and treatment route before booking in Seoul.
Notice: Individual results may vary depending on skin condition, treatment history, and recovery factors. All treatment plans are determined through individual consultation with a board-certified dermatologist. The information on this page is for reference only and does not constitute medical advice or guarantee specific outcomes.
Next Step